|
|
Volumn 17, Issue 21, 2011, Pages 6608-6614
|
|
The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALANINE AMINOTRANSFERASE;
ASPARTATE AMINOTRANSFERASE;
MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;
PAZOPANIB;
PLACEBO;
PROTEIN TYROSINE KINASE INHIBITOR;
RECOMBINANT CYTOKINE;
VASCULOTROPIN INHIBITOR;
ABDOMINAL PAIN;
ADVANCED CANCER;
ALANINE AMINOTRANSFERASE BLOOD LEVEL;
ANOREXIA;
ANTINEOPLASTIC ACTIVITY;
AREA UNDER THE CURVE;
ASPARTATE AMINOTRANSFERASE BLOOD LEVEL;
BRAIN HEMORRHAGE;
BRAIN ISCHEMIA;
DIARRHEA;
DIGESTIVE SYSTEM FISTULA;
DIGESTIVE SYSTEM PERFORATION;
DOSE KIDNEY FUNCTION RELATION;
DRUG APPROVAL;
DRUG CONTRAINDICATION;
DRUG DOSE INCREASE;
DRUG EFFICACY;
DRUG ERUPTION;
DRUG FATALITY;
DRUG MARKETING;
DRUG METABOLISM;
DRUG SAFETY;
DRUG SURVEILLANCE PROGRAM;
DRUG TOLERABILITY;
DYSGEUSIA;
EMBRYOTOXICITY;
ESOPHAGUS VARICES BLEEDING;
EUROPEAN UNION;
FATIGUE;
FOOD;
FOOD DRUG INTERACTION;
GASTROINTESTINAL HEMORRHAGE;
HAIR COLOR;
HAIR DISCOLORATION;
HAND FOOT SYNDROME;
HEALTH CARE ORGANIZATION;
HEART DISEASE;
HEART MUSCLE ISCHEMIA;
HEMATURIA;
HUMAN;
HYPERTENSION;
HYPOTHYROIDISM;
KARNOFSKY PERFORMANCE STATUS;
KIDNEY CARCINOMA;
LIVER FAILURE;
LIVER FUNCTION;
LIVER TOXICITY;
LUNG HEMORRHAGE;
MAXIMUM PLASMA CONCENTRATION;
MUCOSA INFLAMMATION;
MULTICENTER STUDY (TOPIC);
MULTIPLE DRUG DOSE;
NAUSEA;
NONHUMAN;
OUTCOME ASSESSMENT;
PERITONITIS;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
POSTMARKETING SURVEILLANCE;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PROTEINURIA;
QT PROLONGATION;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RECOMMENDED DRUG DOSE;
RECTUM HEMORRHAGE;
RETROPERITONEAL HEMORRHAGE;
REVIEW;
RISK BENEFIT ANALYSIS;
RISK MANAGEMENT;
RISK REDUCTION;
SIDE EFFECT;
SOLID TUMOR;
SUDDEN DEATH;
SURVIVAL TIME;
TERATOGENESIS;
THROMBOEMBOLISM;
TORSADE DES POINTES;
TRANSIENT ISCHEMIC ATTACK;
VOMITING;
WEIGHT REDUCTION;
ANIMALS;
ANTINEOPLASTIC AGENTS;
CARCINOMA, RENAL CELL;
CLINICAL TRIALS AS TOPIC;
HUMANS;
KIDNEY NEOPLASMS;
PYRIMIDINES;
SULFONAMIDES;
|
|
EID: 80455140297
PISSN: 10780432
EISSN: 15573265
Source Type: Journal
DOI: 10.1158/1078-0432.CCR-11-1734 Document Type: Review |
|
Times cited : (26)
|
|
References (12)
|
